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OBJECTIVE—Manyguidelinesrecommendreducedconsumptionofsaltinpatientswithtype
1 diabetes, but it is unclear whether dietary sodium intake is associated with mortality and end-
stage renal disease (ESRD).
RESEARCH DESIGN AND METHODS—In a nationwide multicenter study (the
FinnDiane Study) between 1998 and 2002, 2,807 enrolled adults with type 1 diabetes without
ESRD were prospectively followed. Baseline urinary sodium excretion was estimated on a 24-h
urine collection. The predictors of all-cause mortality and ESRD were determined by Cox
regression and competing risk modeling, respectively.
RESULTS—Themedianfollow-upforsurvivalanalyseswas10years,duringwhich217deaths
were recorded (7.7%). Urinary sodium excretion was nonlinearly associated with all-cause mor-
tality,suchthat individualswiththehighestdaily urinarysodium excretion,aswell asthelowest
excretion,hadreducedsurvival.Thisassociation wasindependent age,sex,duration ofdiabetes,
the presence and severity of chronic kidney disease (CKD) (estimated glomerular ﬁltration rate
[eGFR] and log albumin excretion rate), the presence of established cardiovascular disease, and
systolic blood pressure. During follow-up, 126 patients developed ESRD (4.5%). Urinary so-
dium excretion was inversely associated with the cumulative incidence of ESRD, such that
individuals with the lowest sodium excretion had the highest cumulative incidence of ESRD.
CONCLUSIONS—In patients with type 1 diabetes, sodium was independently associated
with all-causemortalityand ESRD.Althoughwe havenotdemonstrated causality,these ﬁndings
support the calls for caution before applying salt restriction universally. Clinical trials must be
performedindiabeticpatientstoformallytesttheutility/risk ofsodiumrestriction inthissetting.
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B
lood pressure control is a key target
for the prevention and management
of the complications of type 1 di-
abetes. To this end, many treatment
guidelines have promoted the potential
utilityofdietarysaltrestrictioninpatients
with diabetes (1,2), as a means to reduce
blood pressure levels and, with it, poten-
tially modify the risk and severity of com-
plications. However, any restriction in
dietary sodium intake is also associated
withactivationofthesympatheticnervous
system (3) and the renin-angiotensin-
aldosterone system (4) and increased
LDL cholesterol (4). Some studies have
alsosuggestedthatsaltrestrictionreduces
insulin sensitivity in patients with type 2
diabetes (5) and healthy human volun-
teers(6).Inthecontextoftype1diabetes,
and especially in patients with chronic
kidneydisease(CKD)whohavethegreatest
risk of adverse outcomes (7,8), activation
of these pathways may offset or over-
shadow any gains achieved from modest
and transient blood pressure lowering.
Hence, in this study we aimed to deter-
mine the association between dietary salt
intake and 1) all-cause mortality and 2)
end-stage renal disease (ESRD) in 2,807
patients with type 1 diabetes from the
large nationwide multicenter cohort of
Finnish adults with type 1 diabetes (the






Study, with the aim to identify genetic,
clinical, and environmental risk factors
for diabetic nephropathy in patients with
type1diabetes(7,9). InFinnDiane, type1
diabetes was deﬁned as an onset of diabe-
tes before the age of 35 years and perma-
nent insulin treatment initiated within 1
year of diagnosis. For the current study,
outcomes were ascertained in all patients
from the FinnDiane prospective cohort
without ESRD at baseline and who were
enrolled between January 1998 and
December 2002 (n = 2,807). The ethics
committees of all participating centers ap-
proved the study protocol. Written in-
formed consent was obtained from each
patient, and the study was performed
in accordance with the Declaration of
Helsinki.
Cohort characteristics
At baseline, data on medication and di-
abetescomplicationswereregistered with
the use of a standardized questionnaire,
which was completed by the physician
based upon medical ﬁles. Blood pressure
wasmeasuredtwice inthesittingposition
after a 10-min rest, and the average of
these two measurements was used in the
analysis. Height,weight, and waist-to-hip
ratiowererecorded,andbloodwasdrawn
for the measurements of HbA1c, lipids,
and creatinine. The glomerular ﬁltration
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ORIGINAL ARTICLErate (GFR) was estimated using the
Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) formula. Mac-
rovasculardiseasewasdeﬁnedasahistory
of myocardial infarction, a coronary ar-
tery procedure (bypass surgery or angio-
plasty), stroke, limb amputation, or
peripheral artery procedure, which was
veriﬁed from the medical ﬁles. HbA1c
and creatinine were determined by stan-
dardized assays at each center. Serum
lipid and lipoprotein concentrations
were analyzed centrally by automated en-
zymatic methods (Hoffmann-LaRoche,
Basel, Switzerland). In addition, the uri-
nary sodium concentration was measured
in a single 24-h urine collection with an
ion-selectiveelectrode(RocheDiagnostics,
Basel, Switzerland) performed centrally at
the University of Helsinki. During follow-
up all patients were managed by their
own practitioner and diabetes team,
without any attempt to standardize care.
Inparticular,therewerenolimitationsor
requests to modify the diet or sodium in-
take by study organizers.
Ascertainment of outcomes
Deaths from any cause through 17 March
2010 were identiﬁe dv i aas e a r c ho ft h e
Finnish National Death Registry and cen-
ter databases. All deaths were conﬁrmed
with death certiﬁcate data. In each case,
vital status was veriﬁed from the Finnish
National Death Registry. ESRD was de-
ﬁned as the requirement for dialysis or
kidney transplantation and identiﬁed
via a search of the renal registries and
center databases and veriﬁed from med-
ical ﬁles.
Statistical analysis
In this article, we aimed to identify the
predictors of the all-cause mortality and
the cumulative incidence of ESRD. To
evaluate the independent predictors of
all-cause mortality in individuals with
type 1 diabetes, we used Cox proportional
hazards models. Model selection from
candidate variables was accomplished by
minimization of the Akaike and Bayesian
information criteria. Overall, Cox model
ﬁt was assessed by 1) approximation of
cumulative Cox-Snell residuals to (2log)
Kaplan-Meier estimates, residual plots,
and speciﬁc testing of the proportional
hazards assumption and 2) Harrell C sta-
tistic and added-variable goodness-of-ﬁt
tests. Cox model performance was ad-
judged by the explained variation using
5,000 bootstrap repetitions of the whole
dataset, adjusting for covariates (10).
The predictors of the cumulative in-
cidence of ESRD, accounting for the
competing event of pre-ESRD death,
were ascertained using a Fine and Gray
model (11), which extends the Cox pro-
portional hazards model to competing
risk data by considering the subdistribu-
tion hazard. The strength of the associa-
tion between each predictor variable and
the outcome was assessed using the sub-
hazard ratio (12), which is the ratio of
hazards associated with the cumulative
incidence function (CIF) in the presence
of and in the absence of a prognostic fac-
tor. Because standard errors of the Fine-
Gray model are robust (Huber-White
type), model selection was guided by in-
formation criteria (Akaike information
criterion [AIC] and Bayesian information
criterion [BIC]). The model speciﬁcation
was established by residual analysis,
DFBETA measures of inﬂuence across
each model covariate, and formal check
of proportionality by the use of time-
varying covariate effect. The Fine-Gray
modelwasimplementedinStatastatistical
software (V11, 2009; College Station, TX)
using the stcrreg module. In both models,
covariate functional form (including as-
sessment of nonlinear effect) was ad-
judged by residual-by-time analysis,
fractionalpolynomials,and(cubic)regres-
sion splines, where appropriate. The po-
tential for multiple colinearity was tested
using the variance inﬂation factor and
condition number, where variance inﬂa-




The cohort inwhich 24-h urinary sodium
excretion was estimated comprised 2,807
adult patients with type 1 diabetes. The
cohortcharacteristics at baseline are sum-
marizedinTable1.Brieﬂy,approximately
half of the participants were men (51%).
The mean age of the participants was 39
years, with a median duration of diabetes
of 20 years. Forty-seven percent of pa-
tients had hypertension (deﬁned by the
use of antihypertensive agents and/or a
blood pressure .140/90). At baseline,
15% had a urinary albumin excretion
rate (AER) in the microalbuminuric range
and 15% had a urinary AER in the macro-
albuminuric range. Sixty-ﬁvepercent had
a urinary AER in the normoalbuminuric
range. A further 5% of study participants
were unclassiﬁed because of an inade-
quatenumberofurinecollections.Twelve
percent of patients had an estimated GFR
(eGFR) ,60 mL/min/1.73 m
2,m o s t
of whom also had macroalbuminuria.
Urinary sodium excretion
The mean urinary sodium excretion in
Finnish patients with type 1 diabetes was
150 6 20 mmol/day. As previously
described in the Finnish population
(13,14), the mean daily sodium excretion
was signiﬁcantly lower in women (131
mmol/day) than in men (160 mmol/day;
P , 0.001). In addition, sodium excre-
tion was independently associated with
age, duration of diabetes, body mass,
HDL cholesterol levels, the presence of es-
tablished cardiovascular disease, and renal




ble 1), but after adjusting for age and sex
there was no association between urinary
sodium excretion and the achieved level of
blood pressure or the modality of antihy-
pertensive therapy, including the chronic
use of diuretics, as previously shown (15).
Althoughinsulinmaydirectlymodifyrenal
sodium excretion (16), the insulin dose
was not associated with urinary sodium
excretion.
Mortality and urinary sodium
excretion
The median follow-up for survival analy-
ses was 10 years during which 217 deaths
were recorded (7.7%). Urinary sodium
excretion was signiﬁcantly associated
with all-cause mortality (P , 0.001).
This association was nonlinear, such
thatindividualswiththehighestdailyuri-
nary sodium excretion,aswellas the low-
est excretion, had reduced cumulative
survival (Fig. 1). After adjusting for pa-
rameters associated with daily urinary so-
dium excretion, as well as other factors
independently associated with all-cause
mortality (including age, sex, duration
of diabetes, the presence and severity of
CKD [eGFR and log AER]), the presence
of established cardiovascular disease and
systolic blood pressure urinary sodium
excretion remained signiﬁcantly associ-
ated with all-cause mortality on multivar-
iate Cox regression analysis (P , 0.001;
full regression model is presented as
Supplementary Table 2). There were no
signiﬁcant interactions identiﬁed. Nota-
bly, the relationship between sodium in-
takeandmortalitywasindependentofthe
severity of CKD at baseline, the presence
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Dietary salt in type 1 diabetesorabsenceofhypertension,itsseverity,or
its means of treatment.
ESRD and urinary sodium excretion
During a median of 10 years of follow-up
126 patients developed ESRD (4.5%). All
but four of these patients had a urinary
albumin excretion in the macroalbumi-
nuric range at baseline. Consequently, to
examine the association between urinary
sodium excretion and ESRD, we consid-
ered only this subgroup of macroalbumi-
nuric patients (n = 424) with their 122
ESRD events. As with mortality, urinary
sodium excretion was also signiﬁcantly
associated with ESRD (Fig. 2). After ad-
justing for parameters associated with
daily urinary sodium excretion, as well
as other factors independently associated
with ESRD and taking into account the
competing risk of pre-ESRD death,
urinary sodium excretion remained sig-
niﬁcantly associated with the cumulative
incidence of ESRD (P , 0.001). Individ-
ualswiththelowestsodiumexcretionhad
the highest cumulative incidence of ESRD.
ThefullFine-Graycompetingriskmodelis
presented as Supplementary Table 3. No-
tably, this model incorporates an interac-
tion between sodium excretion and
estimated GFR modeled as a cubic regres-
sion spline. The relationship between so-
dium intake and the cumulative incidence
of ESRD was not demonstrated to be asso-
ciated with the presence or absence of hy-
pertension, its severity, or its means of
treatment.
CONCLUSIONS—Many guidelines
recommend and advocate that patients
with type 1diabetesshouldaimtorestrict
their dietary intake of salt (1,2). Such
recommendations have been inferred
from data showing that a reduced sodium
intake can result in a modest short-term
fallinbloodpressureinsome(butnotall)
patients with type 1 diabetes (17). How-
ever, the epidemiological associations be-
tween sodium intake and long-term
outcomes have not been previously ex-
plored speciﬁcally in patients with type
1 diabetes. Small studies have suggested
anassociationbetweendietarysodiumin-
take with proliferative retinopathy (18)
and albuminuria in type 1 diabetes (19).
However, this is the ﬁrst study to show
that dietary sodium intake is associated
with all-cause mortality in patients with
type 1 diabetes and correlated with the
development of ESRD in patients with
macroalbuminuria, after adjusting for
baseline risk factors. Importantly, this as-
sociation appearstobenonlinear,with an
increased risk of death and ESRD in indi-
viduals with low sodium excretion, as
well as reduced survival in those with
high sodium intakes.
That both high and low sodium in-
take may be associated with adverse
mortality outcomes is consistent with
epidemiological data from nondiabetic
individuals. For example, in the Finnish
general population, a high sodium intake
hasbeenassociated with an increased risk
ofmortality(14).Inso farastwo-thirdsof
our patients with type 1 diabetes are free
ofCKDandhypertension,andthesecom-
plications-free individuals have an age-
sex standardized mortality rate not signif-
icantly different from that of the general
population (7,8), similar predictors of
mortality may also be anticipated. At the
sametime,anegativeassociationbetween
sodiumintakeandmortalityhasbeenalso
observed in hypertensive men (20) and in
aggressively treated patients with type 2
diabetes (21). It is possible to speculate
that the balance of diabetic patients en-
rolled in our study, which included both
healthyindividualsandotherswithestab-
lishedcomplications,reﬂectsoneorother
pole, thus cumulatively generating a
U-shaped association between salt excre-
tion and mortality. However, the shape of
this association was consistent across all
subgroups, including those individuals
with or without established renal or cardio-
vascular complications (Supplementary
Table 2), suggesting that other factors are
also involved.
Strengthsofourstudyincludeitsvery
large cohort of individuals with type 1
diabetes, high participation rate, access to
subsidized care (75–100% of costs), and
Table 1—Baseline clinical characteristics of patients with type 1 diabetes from the








Age (years) 38 6 13 39 6 12 39 6 12
Male (%) 32.6* 49.2 71.5*
Duration of diabetes (years) 22 6 12 22 6 12 20 6 11*
Insulin dose (units/kg) 0.7 6 0.2 0.7 6 0.2 0.7 6 0.2
HbA1c (%) 8.4 6 1.5 8.4 6 1.5 8.4 6 1.4
BMI (kg/m
2) 24.7 6 3.4* 25.0 6 3.5 26.1 6 3.5*
Hypertension (%) 44.5* 50.2 53.6*
Blood pressure (mmHg)
Systolic 132 6 18 133 6 18 135 6 18*
Diastolic 78 6 9* 79 6 98 1 6 10*
Antihypertensive medication use (%) 33.6 37.1 39.3*
ACE inhibition 28.9 27.4 24.4
Angiotensin receptor blocker 6.2 5.1 3.8
Calcium channel blocker 7.3 8.5 10.0
b-blocker 9.7 10.3 9.0
Diuretic 9.4 10.0 8.1
Lipid-lowering therapy (%) 10.8 9.5 10.8
Cholesterol (mmol/L)
Total§ 5.0 6 0.9 5.0 6 0.9 5.0 6 1.0
LDL§ 3.1 6 0.8 3.1 6 0.8 3.2 6 0.8*
HDL§ 1.3 6 0.4 1.3 6 0.4 1.3 6 0.4*
Triglycerides (mmol/L) 1.3 6 0.9 1.2 6 0.9 1.3 6 0.9
Any retinopathy (%) 52 50 52
Retinopathy requiring laser therapy (%) 29 31 28
Current smoker (%) 23 24 27
Established macrovascular disease (%) 9.2 7.5 6.4
Normoalbuminuria (%) 68.7 69.9 71.1
Microalbuminuria (%) 16.4 14.5 13.8
Macroalbuminuria (%) 14.9 15.6 15.2
eGFR (mL/min/1.73 m
2)8 4 6 23 84 6 22 87 6 21*
*Versus middle quartiles, univariate P , 0.05 (for independent predictors of baseline urinary sodium ex-
cretion in a multivariate regression model see Supplementary Table 1). §To convert values for cholesterol to
milligrams per deciliter, divide by 0.02586.
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Thomas and Associatescontemporary treatment regimens, includ-
ing a range of insulin regimens, statins,
blockers of the RAS, and self-monitoring
technologies. We used validated methods
to identify deaths, and all deaths in our
cohort were conﬁrmed through death re-
cords. Surveillance bias is unlikely given
the uniform vital status follow-up pro-
cedures used by our staff masked to par-
ticipants’ CKD status levels. In our
questionnaire, we had broad data on
tobacco or alcohol use, diet, education,
socioeconomic status, other possible
confounders (e.g., insulin resistance), or
the severity of disease. Few changes in di-
abetes treatment and health care over the
short study period will have affected mor-
tality results. Our study also speciﬁcally
examined ESRD within the paradigm
of a formal competing risks (Fine-Gray)
model,whichlookedatthecumulativein-
cidence of ESRD while taking into con-
sideration (in an estimation sense) the
competing risk of death. This strategy is
especially important in patients with type
1 diabetes, since cause-speciﬁca n a l y s i s
may be confounded when individuals at
highest risk of ESRD (e.g., macroalbumi-
nuric or hypertensive patients) are also at
increased risk of pre-ESRD mortality.
Another strength of this study is the
fact that the dietary intake of sodium in
our cohort is very similar to that docu-
mentedinthegeneralpopulation, both in
Finland (13,14) and globally (22). We
have also recently published dietary sur-
veys on a subset of 817 FinnDiane pa-
tients, collected with a 3-day food
record completed twice with a 2- to 3-
month interval, describing a mean daily
sodium consumption of 7.2 6 2.0 g/day
(23). Twenty-seven percent of patients
achieved target levels of less than 6 g of
NaCl(23),aﬁgurenodifferenttothegen-
eral Finnish population. Such data sug-
gest that advice to restrict dietary salt
intake in our cohort of diabetic patients
is not promulgated beyond universal rec-
ommendationsforthegeneralpopulation
or is equally ineffective. Although it is
possible that more aggressive recommen-
dations for salt restriction or their uptake
may be more likely in high-risk patients
(confounding by indication), the associa-
tion between salt and adverse outcomes
appeared to be independent of conven-
tional factors that physicians may nor-
mally use to stratify risk.
It is fundamental to state with respect
to the association of sodium and adverse
outcomes that statistical independence
of effect does not imply (strict) causality
(24) and additional trials should be per-
formed to formally test our ﬁndings and
thepotentialutility/riskofsodiumrestric-
tion in the context of diabetes. Any path-
ophysiological mechanisms that may
underlie our ﬁndings also remain to be
established. Certainly, sodium restriction
results in increased atherosclerosis in ex-
perimental models (25). In humans,
salt restriction increased activity of the
renin-angiotensin-aldosterone system
(4) and increased sympathetic activity
(3) and insulin resistance (5,6), each of
whichmaycontributetothedevelopment
and progression of diabetes complica-
tions. We were unable to observe any as-
sociation between sodium intake and
bloodpressureindexesinourcohort.Con-
sistent with these ﬁndings, short-term
studies of salt restriction in patients with
Figure 1—The association between 24-h urinary sodium excretion and all-cause mortality
modeled within the conventional Cox model as a cubic regression spline presented as
Supplementary Table 2.
Figure 2—The cumulative incidence of ESRD over the 10th, 25th, 50th, 75th, and 90th per-
centiles of 24-h urinary sodium excretion, adjusted for other covariate predictors and accounting
for pre-ESRD mortality as the competing risk (full Fine-Gray proportional hazards competing
risk regression model is presented as Supplementary Table 3).
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Dietary salt in type 1 diabetestype 1 diabetes have also revealed variable
outcomes, with both increases and falls in
blood pressure observed in different in-
dividuals, and no net effect overall (17).
Notably, in this study, the clinical charac-
teristics of salt-sensitive patients were not
different from those in whom blood pres-
sure levels rose with salt restriction, par-
ticularly with regard to the presence and
severityofCKD.Thissuggeststhatevenin
the setting of diabetes and CKD, universal
recommendations regarding salt intake
may be problematic.
Several study limitations need to be
considered. First, these studies were also
limited by reliance on sodium excretion
data obtained from a single urine collec-
tion. Because of dietary variability, there
may be substantial variation in salt excre-
tion on a day-to-day basis, meaning that a
single value may not accurately reﬂect
habitual sodium intake. Nonetheless, this
method is regarded as the best way to
estimate dietary sodium intake and sub-
stantially more effective than dietary re-
call. There appears to be only a modest
coefﬁcient of variation (21), comparable
with other commonly used parameters
like lipid levels. Even in the setting of re-
nal impairment, the urinary excretion of
sodium is largely maintained along with
volume homeostasis, as a result of adap-
tations in residual nephrons. This has
been suggested to be because sodium in-
take may be physiologically set (22). Sec-
ond,ourdata areobservational.Although
observational studies have a number of
potential advantages, it is also possible
that associations demonstrated in this
study may be because of confounding
by unmeasured factors or ones that are
difﬁcult to quantify. For example, vari-
ability in dietary sodium intake may be
passivelyassociatedwitharangeofdiffer-
ences in diet composition, processing,
and preparation that may impact adverse
outcomes indiabetic individuals.Inaddi-
tion, the appetite for salt may be associ-
ated with differences in neuroendocrine
effectors that may themselves impact on
the development and progression of dia-
betes complications.
In summary, the association between
sodium intake and adverse outcomes in
type 1 diabetes is complex. In the setting
of type 1 diabetes, individuals with the
lowest sodium excretion (the best avail-
able marker for their low salt intake) have
an increased risk of all-cause mortality and
ESRD. Individuals with a high salt intake
also have an increased risk of mortality. Al-
thoughwehavenotdemonstratedcausality,
these ﬁndings further support the calls for
caution before applying salt restriction
universally (26), since clinical outcomes
may be different or paradoxical in certain
settings.Inparticular,thespeciﬁcrequire-
ments for diabetic individuals should not
be inferred from general population data
but must be validated in studies per-
formed speciﬁcally in diabetic patients.
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